Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations

v3.19.3
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Operating Costs and Expenses:        
General and administrative $ 1,098,000 $ 1,474,000 $ 3,297,000 $ 4,525,000
Research and development 4,144,000 2,846,000 9,156,000 9,788,000
Total Operating Costs and Expenses 5,242,000 4,320,000 12,453,000 14,313,000
Loss from Operations (5,242,000) (4,320,000) (12,453,000) (14,313,000)
Other Income :        
Change in fair value of warrant liability 0 626,000 0 4,064,000
Interest income 92,000 5,000 217,000 20,000
Total Other Income 92,000 631,000 217,000 4,084,000
Net Loss (5,150,000) (3,689,000) (12,236,000) (10,229,000)
Net Loss Attributable to Non-controlling Interest (30,000) (9,000) (73,000) (35,000)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries (5,120,000) (3,680,000) (12,163,000) (10,194,000)
Net Loss Attributable to Common Stockholders $ (5,253,000) $ (3,741,000) $ (12,934,000) $ (10,375,000)
Net Loss Per Share - Basic and Dilutive $ (0.31) $ (0.93) $ (0.79) $ (2.73)
Weighted average number of shares outstanding during the period - Basic and Dilutive 16,805,257 4,028,304 16,313,326 3,802,812
Series A Preferred Stock [Member]        
Other Income :        
Preferred Stock Dividends, Income Statement Impact $ (63,000) $ (61,000) $ (185,000) $ (181,000)
Series B Preferred Stock [Member]        
Other Income :        
Net Loss Attributable to Non-controlling Interest 0      
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries 0      
Preferred Stock Dividends, Income Statement Impact $ (70,000) $ 0 $ (585,000) $ 0